Treatment of Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Stimulation Bilaterally? (SNS)

This study is currently recruiting participants.
Verified March 2012 by University of Aarhus
Sponsor:
Collaborator:
MEDTRONIC DANMARK A/S Arne Jacobsens Alle 17 DK-2300 København S Danmark
Information provided by (Responsible Party):
Jakob Jakobsen, University of Aarhus
ClinicalTrials.gov Identifier:
NCT00913601
First received: June 2, 2009
Last updated: March 21, 2012
Last verified: March 2012

June 2, 2009
March 21, 2012
May 2009
May 2013   (final data collection date for primary outcome measure)
Number of faecal incontinence episodes per week. [ Time Frame: 1, 2, and 3 months after enrolment to the project ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00913601 on ClinicalTrials.gov Archive Site
  • Days with faecal soiling. [ Time Frame: 1, 2, and 3 months after enrolment to the project ] [ Designated as safety issue: No ]
  • Days with faecal urgency. [ Time Frame: 1, 2, and 3 months after enrolment to the project ] [ Designated as safety issue: No ]
  • Wexner incontinence score. [ Time Frame: 1, 2, and 3 months after enrolment to the project ] [ Designated as safety issue: No ]
  • Anal physiological changes during SNS bilateral versus unilateral. [ Time Frame: 1, 2, and 3 months after enrolment to the project ] [ Designated as safety issue: No ]
  • Quality of life assessment (Rockwood - Fecal incontinence quality of life) [ Time Frame: 1, 2, and 3 months after enrolment to the project ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Treatment of Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Stimulation Bilaterally?
Treatment of Idiopathic Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Implantation and Stimulation of Permanent Electrodes Bilaterally - a Double-blinded Randomized Cross-over Trial

Faecal incontinence is a devastating condition causing psychological stress, affecting daily living and influences quality of life. Faecal incontinence affects 2,2 to 5 % of the adult population. The magnitude of the problem is probably underestimated, because most patients don't discuss this affliction with their general practitioner. A new treatment, sacral nerve stimulation (SNS), has over the last decade given hope to these patients. The treatment is divided in two; first a test operation (PNE-test) has to reveal if the patient will benefit from treatment with permanent sacral nerve stimulation. Second if the patient benefit from the PNE-test, they proceed to final implant. 75-80% of the patients with idiopathic fecal incontinence benefit from the PNE-test, 70% of those get satisfactory functional results and the remaining 30% get suboptimal improvement in continence after permanent unilateral sacral nerve stimulation. The aim of this project is to investigate if bilateral sacral nerve stimulation can produce better fecal continence results than standard unilateral stimulation, through a double blind, randomized crossover study.

Sacral nerve stimulation is a very good and effective treatment for faecal incontinence The method was introduced to patients with voiding disorders in 1981. In 1995 sacral nerve stimulation was used for three patients with faecal incontinence, two were afterwards fully continent. The method has over the last decade been used increasingly in Europe. The method is now used routinely in the treatment of faecal incontinence in Europe.

Recent studies have shown that the effect of sacral nerve stimulation is due to a neuromodulation in the central nervous system, whereas direct stimulation of efferent nerves to anal sphincter and the pelvic floor has less significance.

The sacral nerve stimulation is performed in two steps, first a test stimulation, if positive the patients proceed to permanent implant.

Test stimulation (PNE-test) is performed over a 3 week period. If this test stimulation produces a decrease in incontinence episodes of more than 50 per cent, a permanent electrode and neurostimulator are implanted. The test period has a success rate of approximately 75-80% in patients with idiopathic fecal incontinence or incontinence after anal surgery. These 75-80% will normal be candidates to unilateral implantation of permanent electrode and neurostimulator.

All permanently implanted has less incontinence symptoms after the treatment. Satisfactory continence results after permanent implantation are seen in 70% of the patients, the remaining 30% only obtain a suboptimal efficacy. It is unclear whether these patients could have a more optimal function if they were stimulate on more than one sacral nerve simultaneously.

Hypothesis: Is it possible to improve the functional result in faecal incontinent patients treated with routine unilateral sacral nerve stimulation by stimulating the sacral nerves bilaterally.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Fecal Incontinence
Device: Medtronic INTERSIM II - 3058
Medtronic INTERSIM II - 3058 Impuls Generator
Other Names:
  • Medtronic INTERSIM II - 3058
  • Impuls Generator
  • Experimental: Dextra
    Unilateral sacral nerve stimulation dextra for 4 weeks
    Intervention: Device: Medtronic INTERSIM II - 3058
  • Experimental: Sinistra
    Unilateral sacral nerve stimulation sinistra 4 weeks
    Intervention: Device: Medtronic INTERSIM II - 3058
  • Experimental: Bilateral
    Bilateral sacral nerve stimulation 4 weeks
    Intervention: Device: Medtronic INTERSIM II - 3058

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
May 2014
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed Consent
  • Diagnosed with idiopathic faecal incontinence and planned sacral nerve stimulation
  • Age> 40 years normal sigmoid/colonoscopic prior to operation

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Patients who are not deemed able to follow the planned testing program, including mental illness or mentally unstable patients
  • Medication with known effects on gastrointestinal motility, thyroid disease, diabetes, coeliaki, neurological disorders.
  • Irritable Bowel Syndrome
Both
18 Years and older
No
Contact: Jakob K Jakobsen, MD 89497527 ext 0045 Jakob_Jakobsen@hotmail.com
Contact: Soren Laurberg, Professor, DMSc, MD. 89497715 ext 0045 soerlaur@rm.dk
Denmark
 
NCT00913601
001
Yes
Jakob Jakobsen, University of Aarhus
University of Aarhus
MEDTRONIC DANMARK A/S Arne Jacobsens Alle 17 DK-2300 København S Danmark
Principal Investigator: Jakob K Jakobsen, MD Anal Physiology Laboratory, Surgical Research Section 900, Aarhus University Hospital, Denmark
University of Aarhus
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP